AU2002360269A1 - Method for inhibiting the formation of seromas using factor XIII - Google Patents
Method for inhibiting the formation of seromas using factor XIIIInfo
- Publication number
- AU2002360269A1 AU2002360269A1 AU2002360269A AU2002360269A AU2002360269A1 AU 2002360269 A1 AU2002360269 A1 AU 2002360269A1 AU 2002360269 A AU2002360269 A AU 2002360269A AU 2002360269 A AU2002360269 A AU 2002360269A AU 2002360269 A1 AU2002360269 A1 AU 2002360269A1
- Authority
- AU
- Australia
- Prior art keywords
- factor
- formation
- seromas
- inhibiting
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
METHOD FOR INHIBITING THE FORMATION OF SEROMAS USING FACTOR xm
BACKGROUND OF THE INVENTION
Seromas are collections of lymph usually present as painless swellings within a wound or below flaps. These often develop in wounds involving dissection in lymph node-bearing areas, for example axillae, neck, groin etc., or in areas where significant dead space remains such as after abdominal-perineal resection, total mastectomy or in breast reduction procedures either for females or to treat gynecomastia in males. The seromas prevent adequate tissue approximation or may become secondarily infected.
The primary cause lies in the failure to identify and control lymphatic vessels during dissection. Though lymph is a protein-rich fluid, electrocauterization is ineffective to prevent seroma formation. Thus, there is a need to develop a treatment to prevent the formation of seromas.
DESCRIPTION OF THE INVENTION The present invention fills this need by administering factor XIH to patients who have undergone surgery to inhibit the build-up of fluids or seromas beneath the skin where the surgery took place or a wound has occurred. The factor XIH may be applied locally in solution beneath the skin or administered systemically. The factor XHI solution can be administered prior to surgery, prior to suturing of the surgical site or can be injected beneath the skin after surgery. If the factor XHI is administered locally, it may be activated or non-activated, or the non-activated factor Xm may be applied in conjunction with activated alpha-thrombin. The activated thrombin would then activate the factor XHI. Activated thrombin can be administered locally at a concentration of about 0.5 mg/mL of solution. A method for producing human recombinant thrombin can be found in U.S. Patent No. 5,502,034.
Factor Xm, also known as fibrin-stabilizing factor, circulates in the plasma at a concentration of 20 μg/ml. The protein exists in plasma as a tetramer comprised of two A subunits and two B subunits. Each subunit has a molecular weight of 83,000 Da, and the complete protein has a molecular weight of approximately 330,000 Da. Factor Xm catalyzes the cross-linkage between the γ-glutamyl and ε-lysyl groups of different fibrin strands. The catalytic activity of factor XH resides in the A subunits. The B subunits act as carriers for the A subunits in plasma factor Xm. Recombinant factor X can be produced according to the process described in European Patent No. 0 268 772 Bl. The level of factor XQI in the plasma can be increased by administering a factor Xm concentrate derived from human placenta called FIBROGAMMIN® (Aventis Corp.) or by administration of recombinant factor xm.
As stated above, administration of factor XM to a subject is may be administered locally at the site of the wound or systemically. If administered systemically, the factor Xm is generally administered intravenously. When administering therapeutic proteins by injection, the administration may be by continuous infusion or by single or multiple boluses. A pharmaceutical composition comprising factor Xm can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient patient. A suitable pharmaceutical composition of factor Xm will contain ImM EDTA, lOmM glycine, 2% sucrose in water. An alternative formulation will be a factor Xm composition containing 20 mM histidine, 3% wt/volume sucrose, 2 mM glycine and .01% wt/vol. polysorbate, pH 8.
Other suitable carriers are well known to those in the art. See, for example, Gennaro (ed.), Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company 1995).
Administration of Factor XIII
The levels of factor Xm in an individual can be determined by assays well known in the art such as the BERICHROM F Xm assay (Dade Behring Marburgh GmbH, Marburg, Germany). The normal adult has an average of about 45 ml of plasma per kg of body weight. Each liter of blood has 1000 units (U) of factor XE. The amount of factor XE administered should be enough to bring an individual's level of factor Xm in the plasma to 100% of normal plasma or slightly above to 1-5% above normal. A dose of .45 U/kg would raise the level of factor Xm by about 1% compared to normal. One unit of factor XM is about 10 μg of recombinant factor Xm, which contains only the dimerized A subunit. Thus, to raise the level of factor XHI by 1%, one would administer about 4.5 μg of the A2 subunit per kilogram weight of the individual. So to raise the level 30% of normal, one would administer 13.5 U/kg. For a 75 kg individual this would be about 1,012.5 U. Some patients may have consumptive coagulopathies that involve factor XHI losses. In such cases, a higher dosing (e.g., 1- 2U/kg-%) or multiple dosing of factor X (e.g., l-2U/kg-%-day) may be required.
Example 1
The Use of Factor XIII to Prevent Seroma Formation in a
Rat Seromal Mastectomy Model
Object of the Experiment
The object of the experiment was to determine if factor Xm when given systemically would influence seromal fluid formation using a rat mastectomy model.
Background Seromas are the most common postoperative complication for patients undergoing a mastectomy. The formation of these fluid collections is facilitated by the disruption of lymphatics and blood vessels as well as by the creation of large potential voids beneath the skin. Postoperative problems due to seroma formation include delayed wound healing, flap necrosis, lymph edema of the arm and infection.
Factor Xm PreparationFactor X was provided by ZymoGenetics, Inc., Seattle WA in bottles containing 13.2 mg of lyophilized factor XIH containing 0.3 mM ethylenediaminetetraacetic acid (EDTA), 31 mM glycine, and 6.2% sucrose. The lyophilized factor Xm was reconstituted with 3.3 mL of sterile water and pipetted into 0.5 mL aliquots and stored in a freezer at -20° C.
Vehicle Preparation
The vehicle preparation was a lyophilized powder comprised of 0.3 mM EDTA, 31 mM glycine and 6.2% sucrose. This was reconstituted with 3.3 ml of sterile water and pipetted into 0.5 mL aliquots and stored in a freezer at -20° C. After thawing, 0.5 mL of bovine serum albumin (BSA) was added to each vial.
Experimental Procedure
The rats were anesthetized with isoflurane (3% isoflurane, 1% oxygen) and a catheter was inserted into the jugular vein of each rat. Two to three days following catheter insertion, eleven rats received a single intravenous bolus injection through the catheter of the vehicle preparation (the control group) and 12 rats received a single bolus injection of 1 mg/kg of the factor Xm preparation (the experimental group) 30 minutes prior to a left side radical mastectomy. The mastectomy consisted of removal of the pectoralis muscle, lymphatic tissue including nodes (3 or more) and traumatization of subcutaneous lymphovasculature surface. The traumatization the lymphovasculature occurred by scraping 50 times the inner surface of the elevated skin flap with a No. 22 scalpel blade. Five days following mastectomy, the rats were anesthetized with urethane anesthesia. Blood samples were taken for analysis. Seromal fluid was aspirated and weighed from each rat to determine seromal fluid volume and factor X content.
Results
No significant differences were observed between the Control and Experimental rats for the following: hematology, clinical blood chemistry and factor Xm levels. A significant difference was observed in seromal fluid volume aspirate at time of sacrifice (day 5). The control group averaged 2.7 mL of seromal fluid and the group to whom factor XHI was administered averaged 1.4 mL of seromal fluid. Thus factor XE was effective in inhibiting the formation of seromal fluid.
Claims (5)
1. A method for inhibiting the formation of a seromal or serous fluid at the site of surgery or a wound in a mammal comprising administering to said mammal a therapeutically effective amount of factor XM.
2. The method of claim 1 wherein the factor Xm is administered systemically.
3. The method of claim 1 wherein the factor XM is administered locally at the site of the surgery or wound.
4. The method of claim 3 wherein the factor XM is activated.
5. The method of claim 3 wherein the factor XM is administered in conjunction with activated thrombin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32807001P | 2001-10-09 | 2001-10-09 | |
US60/328,070 | 2001-10-09 | ||
PCT/US2002/032450 WO2003037249A2 (en) | 2001-10-09 | 2002-10-09 | Method for inhibiting the formation of seromas using factor xiii |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002360269A1 true AU2002360269A1 (en) | 2003-07-10 |
AU2002360269B2 AU2002360269B2 (en) | 2007-03-22 |
Family
ID=23279383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002360269A Ceased AU2002360269B2 (en) | 2001-10-09 | 2002-10-09 | Method for inhibiting the formation of seromas using factor XIII |
Country Status (10)
Country | Link |
---|---|
US (2) | US6890903B2 (en) |
EP (1) | EP1434590B1 (en) |
JP (1) | JP2005507926A (en) |
AT (1) | ATE388715T1 (en) |
AU (1) | AU2002360269B2 (en) |
CA (1) | CA2463530A1 (en) |
DE (1) | DE60225576T2 (en) |
ES (1) | ES2303561T3 (en) |
IL (2) | IL161189A0 (en) |
WO (1) | WO2003037249A2 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3621371A1 (en) | 1986-03-12 | 1987-09-17 | Behringwerke Ag | GENETIC PRODUCTION OF FACTOR XIIIA |
EP0268772B1 (en) | 1986-09-19 | 1995-04-26 | ZymoGenetics, Inc. | Expression of biologically active factor XIII |
JPS63196520A (en) | 1987-02-09 | 1988-08-15 | Hoechst Japan Kk | Remedy for ulcerative colitis |
US5612456A (en) * | 1988-11-14 | 1997-03-18 | Zymogenetics, Inc. | Factor XIII compositions |
US5318524A (en) * | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
EP0691850B1 (en) | 1993-03-30 | 2002-09-25 | Hoechst Japan Limited | Factor xiii for treatment of skin wounds |
AU3862900A (en) * | 1999-03-01 | 2000-09-21 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
-
2002
- 2002-10-09 JP JP2003539595A patent/JP2005507926A/en active Pending
- 2002-10-09 AT AT02795514T patent/ATE388715T1/en not_active IP Right Cessation
- 2002-10-09 IL IL16118902A patent/IL161189A0/en unknown
- 2002-10-09 AU AU2002360269A patent/AU2002360269B2/en not_active Ceased
- 2002-10-09 DE DE60225576T patent/DE60225576T2/en not_active Expired - Lifetime
- 2002-10-09 CA CA002463530A patent/CA2463530A1/en not_active Abandoned
- 2002-10-09 EP EP02795514A patent/EP1434590B1/en not_active Expired - Lifetime
- 2002-10-09 US US10/268,180 patent/US6890903B2/en not_active Expired - Fee Related
- 2002-10-09 WO PCT/US2002/032450 patent/WO2003037249A2/en active IP Right Grant
- 2002-10-09 ES ES02795514T patent/ES2303561T3/en not_active Expired - Lifetime
-
2004
- 2004-03-31 IL IL161189A patent/IL161189A/en not_active IP Right Cessation
-
2005
- 2005-03-16 US US11/081,322 patent/US7153830B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0526544B1 (en) | Therapeutic uses of actin-binding compounds | |
IE64080B1 (en) | Pharmaceutical for subcutaneous administration containing polypeptides | |
EP0716611B1 (en) | C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction | |
Liebman et al. | Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII | |
Atiyeh et al. | Local recombinant tissue plasminogen activator (rt‐PA) thrombolytic therapy in microvascular surgery | |
EP1434590B1 (en) | Method for inhibiting the formation of seromas using factor xiii | |
AU2002360269A1 (en) | Method for inhibiting the formation of seromas using factor XIII | |
Ghirardini et al. | Clinical evaluation of subcutaneously administered DDAVP | |
US20090036361A1 (en) | Use of Blood Coagulation Factor XIII for Treating Hemophilia A | |
JP2783367B2 (en) | Heparin-containing preparations | |
JPH03190823A (en) | Erythropoietin hypodermic or intramuscular administration agent | |
Badalamente et al. | Recovery after delayed nerve repair: influence of a pharmacologic adjunct in a primate model | |
WO1993007890A1 (en) | Treatment of haemophilia | |
Ghirardini et al. | Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies | |
Maeda et al. | Continuous local intraarterial infusion of antithrombotic agents for epigastric flap transfer in rabbit | |
EP1550455A1 (en) | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation | |
Levy et al. | A comparison of human recombinant tissue-type plasminogen activator and urokinase in microsurgical thrombolysis in the rat | |
US7115559B2 (en) | Method for treating coumarin-induced hemorrhage | |
JPH11199508A (en) | Organ failure-treating agent | |
Parodi et al. | Gabexate mesilate, a new synthetic serine protease inhibitor: a pilot clinical trial in valvular heart surgery | |
WO2022251645A1 (en) | Hyaluronidase composition for intravenous administration and method of using the same | |
AU2002323670A1 (en) | Method for treating coumarin-induced hemorrhage | |
GB2197195A (en) | Urokinase compositions for treating thrombosis | |
JPH08268910A (en) | Drug for hypodermic administration of protein c | |
SLADE et al. | Postsurgical hemorrhage in dogs anticoagulated with ancrod (arvin) |